Potential molecular communication of blood and synovium through ligand-receptor interactions in osteoarthritis

骨关节炎中血液和滑膜通过配体-受体相互作用进行潜在分子通讯

阅读:5

Abstract

INTRODUCTION: Osteoarthritis (OA) is a common degenerative joint disease resulting from the breakdown of multiple joint tissues, remains a leading cause of disability with limited therapeutic options. Synovitis is one of the reasons of OA progression, while communication between blood and synovium during disease process is still unclear. METHODS: We used transcriptomic datasets from blood and synovium of healthy controls and OA patients to investigate potential molecular crosstalk between blood and synovium in OA pathogenesis through ligand-receptor pairs. RESULTS: Ligand-receptor pair analysis revealed 129 ligands and 137 receptors differentially expressed in blood, and 108 ligands and 86 receptors in synovium. Gene ontology enrichment analysis of differentially expressed ligands indicated receptor ligand activity in both tissues, with blood enriched in leukocyte migration, cell chemotaxis, and leukocyte chemotaxis, and synovium in negative regulation of response to external stimulus, epithelial cell proliferation, and cell chemotaxis. Further protein-protein interaction (PPI) network analysis showed that blood ligands were mainly associated with inflammation and immunity (IL6, IL1B, IL23A, IFNA1, and TNF), while several synovium ligands were linked to angiogenesis (TGFB1, FGF7, and PDGFA). Based on ligand-receptor interactions and PPI network of differentially expressed ligands, we predicted and constructed molecular communication map between blood and synovium. Immunofluorescence staining of synovium showed more blood micro-vessels in OA patients and elevated IL6 and IL1B expression levels, suggesting that synovial inflammation might partly originate from pro-inflammatory cytokines in blood. DISCUSSION: These findings offered new understanding of the molecular mechanisms underlying blood and synovium communication in OA, and provided potential therapeutic drug targets for OA treatment to simultaneously modulate systemic inflammation and local angiogenesis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。